Histaglobulin or immunoglobulin/histamine complex (IHC) has been used globally to treat allergic diseases for several decades. It is a sterile, non-allergen-specific immunotherapeutic agent made up of histamine dihydrochloride and human immunoglobulin as the main components. Histaglobulin effectively treats allergic rhinitis, bronchial asthma, chronic urticaria, atopic dermatitis, and many other allergic conditions. It can be given over a long period without any safety concerns. However, despite being used for several decades for chronic allergic conditions, no reviews or systematic reviews (SRs) comprehensively cover the efficacy and safety of histaglobulin/IHC in various chronic allergic conditions. The publicly available literature on its efficacy and safety in various chronic allergic conditions consists only of small open-label prospective studies, case reports, or case series. This systematic review was undertaken to provide a comprehensive view of the efficacy, safety, and dosing schedule of histaglobulin in common chronic allergic dermatological and respiratory conditions such as chronic urticaria, atopic dermatitis, allergic rhinitis, and bronchial asthma. Further, the SR explored the role of histaglobulin in other conditions such as psoriasis, cutaneous drug allergies, Pfeiffer-Weber-Christian disease with multiple food allergies/atopic dermatitis, and primary eosinophilic colitis. The SR also covers the role of histaglobulin in treating allergic psychiatric manifestations. This is the first SR that documented and concluded that histaglobulin could safely achieve a long-term symptoms-free state in chronic allergic conditions such as chronic urticaria, atopic dermatitis, allergic rhinitis, and asthma. The studies captured in the SR show that histaglobulin can be given for prolonged periods as weekly injections or more frequently (at intervals of 4 days) until completely symptom-free or with significant improvement from allergic symptoms. The SR also identified the need for large multicentre prospective, double-blind, randomized controlled trials, prospective well-designed open-label trials, and observational real-world studies to document the efficacy (including remission) and safety benefits of histaglobulin in various types of chronic allergic conditions not responding to conventional treatments.

1. Doll RJ, Joseph NI, McGarry D, Jhaveri D, Sher T, Hostoffer R. Epidemiology of Allergic Diseases. In: Allergy and Asthma: The Basics to Best Practices [Internet]. Cham: Springer International Publishing; 2019 [cited 2024 May 4]. p. 31–51. Available from: https://doi.org/10.1007/978-3-030-05147-1_2
2. Krishna MT, Mahesh PA, Vedanthan PK, Mehta V, Moitra S, Christopher DJ. The burden of allergic diseases in the Indian subcontinent: barriers and challenges. The Lancet Global Health. 2020 Apr 1;8(4):e478–9.
3. Narayana J, Shanthi T, Bharadwaj S. Efficacy of histaglobulin on allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 1997 Jan;49(1):77–9.
4. Kumar S, Dhillon SS, Brar B, Singh A. Comparative Evaluation of the Therapeutic Efficacy and Safety of Injected Histaglobulin versus Autologous Serum Therapy in Chronic Urticaria. J Clin Aesthet Dermatol. 2021 Mar;14(3):38–41.
5. Rajesh G, Keerthi S, Karthikeyan K, Venkatesan M. Weekly injection of histaglobulin produces long-term remission in chronic urticaria: A prospective clinical study. Indian J Pharmacol. 2016;48(3):292–7.
6. Vignesh Nambi R, Gurusamy S, Danny G, Nagaraju S. A Comparative Study of Autologous Serum Therapy and Histaglobulin in Chronic Urticaria: Underutilized Modalities Revisited! Medical Journal of Dr DY Patil University [Internet]. 2023 Oct 11 [cited 2024 Apr 10]; Available from: https://journals.lww.com/mjdy/abstract/9000/a_comparative_study_of_autologous_serum_therapy.99891.aspx
7. Kim HS, Noh G. Immunotherapy using Histobulin^TM in psoriasis: A case report. Clin Case Rep. 2022 May 12;10(5):e05831.
8. Noh G. Immunotherapy using Histobulin in atopic dermatitis. Clin Case Rep. 2020 Nov 11;9(1):113–7.
9. Nahm DH, Lee ES, Park HJ, Kim HA, Choi GS, Jeon SY. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. Int Arch Allergy Immunol. 2008;146(3):235–40.
10. Verma A, Sachan A, Singh A, Sachan S. Effect of histaglobulin in allergic rhinitis- a prospective study. Journal of Evidence based Medicine and Healthcare. 2018 Dec 10;5(50):1–7.
11. Jutel M, Agache I, Zemelka-Wiacek M, Akdis M, Chivato T, del Giacco S, et al. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. Allergy. 2023;78(11):2851–74.
12. Kim HS, Noh G. Induction of remission in chronic urticaria by immunotherapy using immunoglobulin/histamine complex (Histobulin^TM): a case report. Allergy Asthma Clin Immunol. 2021 Nov 12;17(1):116.
13. Liebhart J, Zak-Najmark T, Ma?olepszy J, Nadobna G, Liebhart E. Changes of histaminopexy in patients with bronchial asthma and chronic urticaria after histaglobin administration. Arch Immunol Ther Exp (Warsz). 1986;34(4):385–9.
14. Mohanty M, Mohapatra S, Pattnaik K, Swain T. Case Report- Prevention of multiple drug allergy by histaglobulin. Indian Journal of Pharmacology (ISSN: 0253-7613) Vol 38 Num 1. 2006 Jan 1;38.
15. Sivanandhan K, Dhanalakshmi S. A Novel Method for Treating Bronchial Asthma with Newly Designed Histaglobulin Therapy. Int J Pharm Bio Sci [Internet]. 2022 [cited 2024 Apr 12];13(3). Available from: http://ijpbs.net/abstract.php?article=7092
16. Kirtchev P, Frankland AW. The Histamine Binding Power of Human Serum from Allergic and Non-Allergic Subjects. Allergy. 1965;20(3):153–9.
17. Gelfand HH, Cinder JC, Grant SF, Soiffer M. Evaluation of histamine-gamma globulin (histaglobin) in the treatment of various allergic conditions. Ann Allergy. 1963 Mar;21:150–5.
18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;n71.
19. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021 Mar 29;n160.
20. Higgins J, Savovi? J, Page M, Elbers R, Sterne J. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). In: Cochrane Handbook for Systematic Reviews of Interventions version 64 (updated August 2023) [Internet]. Cochrane; 2023 [cited 2023 Dec 5]. Available from: https://training.cochrane.org/handbook/current/chapter-08
21. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343:d5928.
22. Sterne JA, Hernán MA, Reeves BC, Savovi? J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919.
23. Sterne J, Hernán M, McAleenan A, Reeves B, Higgins J. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). In: Cochrane Handbook for Systematic Reviews of Interventions version 64 (updated August 2023) [Internet]. Cochrane; 2023 [cited 2024 Apr 11]. Available from: https://training.cochrane.org/handbook/current/chapter-25
24. Sachdeva S, Gupta V, Amin SS, Tahseen M. CHRONIC URTICARIA. Indian J Dermatol. 2011;56(6):622–8.
25. Godse KV. Urticaria Meter. Indian J Dermatol. 2012;57(5):410–1.
26. Khemani UN, Sajgane AA. Efficacy of Injection Histaglobulin in Treatment of Chronic Urticaria. JCDR [Internet]. 2021 [cited 2024 Apr 10]; Available from: https://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2021&volume=15&issue=4&page=WC09&issn=0973-709x&id=14825
27. Godse K, Tare D, Gawali R. Single centre experience with histaglobin as an adjunctive treatment of chronic urticaria: A post marketing surveillance study. IP Indian Journal of Clinical and Experimental Dermatology. 2019;5(3):243–8.
28. Thota S mangadevi. Efficacy of Injection Histoglob in Treatment of Chronic Urticaria-A Prospective Study. IOSR-JDMS. 2019;18(3):57–62.
29. Kumar YHK, Bhaskar S, Shankar K. Comparative Study of Positive Versus Negative Autologous Serum Skin Test in Chronic Spontaneous Urticaria and its Treatment Outcome. N Am J Med Sci. 2016 Jan;8(1):25–30.
30. Chaudhari A, Mehta H, Agrawal N. Comparative study of effectiveness of autologous serum and histaglobulin in autologous serum skin test positive and negative cases of chronic urticaria. Indian Journal of Allergy, Asthma and Immunology. 2019 Jun;33(1):25.
31. Kim HS, Noh G. Effects of the immunoglobulin/histamine complex on panic disorder concurrent with chronic spontaneous urticaria: a case report. Journal of Medical Case Reports. 2023 Jul 28;17(1):341.
32. Noh G, Cho S. Effects of Histobulin on Depression and Anxiety in Chronic Urticaria: Psychiatric Manifestations or Psychiatric Comorbidities of Chronic Urticaria?: A Case Report [Internet]. 2020 [cited 2024 Apr 26]. Available from: https://www.researchsquare.com/article/rs-94970/v1
33. Kim HS, Noh G. Effects of Histobulin (Immunoglobulin/Histamine Complex) on Depression and Anxiety in Chronic Urticaria: Psychiatric Manifestations or Psychiatric Comorbidities of Chronic Urticaria?: A Case Report. Journal of Clinical & Experimental Immunology. 2021 Nov 30;6(6):390–6.
34. Noh G, Han CW. Intravenous Immune Globulin (IVIG) Therapy After Unsuccessful Treatment with Corticosteroid and Cyclosporine A in Pfeifer-Weber-Christian Disease: A Case Report. Am J Case Rep. 2021 Jan 4;22:e929519-1-e929519-7.
35. Noh G. Histobulin as a complementary but essential therapeutic for Intravenous Immune Globulin Therapy of Pfeiffer-Weber-Christian disease with multiple allergic diseases and its effects on allergic disease: A case report. Clinical Case Reports. 2021;9(2):966–72.
36. Madhukar M, Paparaja S. Comparative study of therapeutic effect of histaglobulin with nasal steroids in allergic rhinitis: A hospital based prospective study. MIJOENT [Internet]. 2019;11(2). Available from: https://www.medpulse.in/ENT/Article/Volume11Issue2/ENT_11_2_1.pdf
37. Prasenajith L. A prospective study to compare the therapeutic effects of histaglobulin and nasal steroids in allergic rhinitis. J Cardiovasc Dis Res [Internet]. 2023;14(7). Available from: https://www.jcdronline.org/admin/Uploads/Files/64b8cb1c48fca3.75769622.pdf
38. Fuchs E, Gronemeyer W, Brückner-de Velliet M. The Possibility of Affecting Allergic Reactions by Histamine-Gamma-Globulin Compound. International Archives of Allergy and Applied Immunology. 2009 Jul 30;66(Suppl. 1):291–2.
39. Sivanandhan K. Abstract No 459, Asthma - a curable disease in Abstracts of the XX World Allergy Congress^TM 2007 December 2-6, 2007, Bangkok, Thailand. World Allergy Organ J. 2008 Nov 15;1(Suppl 3):A1–1013.
40. Tanaka Z. Experiences with Histaglobulin in patients of bronchial asthma. PMJ. 1977;15(3).
41. Kim HS, Noh G. Treatment of primary eosinophilic colitis using immunoglobulin/histamine complex. Clinical Case Reports. 2023;11(1):e6885.
42. Nikitina NM. [Histaglobin in the treatment of eczema and neurodermatitis in children]. Pediatriia. 1966 Mar;45(3):38–41.
43. Karagezian MA. [Treatment of allergic dermatitis with repeated courses of injection of histaglobin]. Sov Med. 1967 Sep;30(9):136–7.
44. Karagesian MA. [Treatment of occupational allergic dermatitis and eczema with histaglobin]. Sov Med. 1974 Jul;0(7):122–5.
45. Skripkin IK, Kashtanova MG, Somov BA, Butov IS, Putintseva SV. [Use of histoglobin in the treatment of some dermatoses]. Sov Med. 1971 Jan;34(1):124–6.
46. Butovetski? LD, Bannikov VK. [Treatment of some dermatoses with histoglobin]. Sov Med. 1971 Jan;34(1):126–9.
47. Shevliakov LV. [Histaglobin treatment of chronic urticaria and occupational dermatoses]. Vestn Dermatol Venerol. 1973 Feb;47(2):62–3.
48. Niamdorzh T. [Histaglobin treatment of children with eczema]. Vestn Dermatol Venerol. 1972 Nov;46(11):71–3.
49. Iskakov TK. [Experiences in the use of histaglobin in young children, suffering from bronchial asthma and asthmatic bronchitis]. Pediatriia. 1966 Jul;45(7):23–7.
50. Sokolova TS, Fedotova AM, Iskakov TK. [Treatment of bronchial asthma in children with histaglobin and its effect on several aspects of histamine metabolism]. Vopr Okhr Materin Det. 1968 Aug;13(8):32–6.
51. Kondrat’ev GG, Sergeev VP. [Treatment of eczema with histaglobin]. Vestn Dermatol Venerol. 1968 Aug;42(8):65–7.
52. Tikhomirova NV. [Effect of histaglobin therapy on the antihistamine factor in chronic relapsing urticaria]. Vestn Dermatol Venerol. 1970 Aug;44(8):24–7.
53. Five?ski? VD. [Local use of histaglobin in vasomotor rhinitis]. Zh Ushn Nos Gorl Bolezn. 1974;0(2):31–5.
54. Rapoport ZZ, Shvetskaia AF, Zinov’eva LI. [Use of histaglobin in the treatment of bronchial asthma]. Sov Med. 1973 Jul;36(7):139–40.
55. Borodin IP, Egorova-Mezhevalova AG. [THE USE OF A COMBINATION OF GAMMA-GLOBULIN WITH HISTAMINE (HISTAGLOBIN) FOR THE TREATMENT OF ALLERGIC DISEASES]. Sov Med. 1963 May;26:74–9.
56. Germanets II, Rezenkina LD, Anton’ev AA. [Complex therapy of occupational allergic dermatoses with pyrogenal and histaglobin]. Gig Tr Prof Zabol. 1974 Feb;18(2):22–5.
57. Stadchenko NA, Teliiants SN. [Experience in the use of Histaglobin in allergic diseases]. Sov Med. 1966 Aug;29(8):73–6.
58. Rudzki E, Czubalski K. [Results of treatment of chronic urticaria, prurigo and pruritus with histaglobin]. Przegl Dermatol. 1967;54(5):571–4.
59. Chmielewska-Szewczyk D, Szczypiorski K. [Histaglobin treatment of bronchial asthma in children]. Pediatr Pol. 1970 Jul;45(7):807–14.
60. Jankowska R, Ma?olepszy J, Nowak I. [Influence of histaglobin therapy on skin tests and clinical symptoms in patients with atopic bronchial asthma]. Pneumonol Alergol Pol. 1992;60(11–12):69–72.
61. Krawczuk J. [Histaglobin in the prevention and treatment of recurrent obturative respiratory tract infections in children]. Pediatr Pol. 1974 Dec;49(12):1525–9.
62. Chyrek-Borowska S, Bogdanikowa B, Droxd J. [Histaglobin in treatment of allergic diseases with reference to serum protein determination]. Pol Tyg Lek. 1971 Sep 13;26(37):1432–5.
63. Tikhi? AK, Levchenko LM. [Use of apizatron and histaglobin in the overall treatment of bronchial asthma in children]. Pediatr Akus Ginekol. 1974;(1):11–3.
64. Bezrukov LA, Boriakovski? VG, Dziuba OL, Kozachek VI, Lasitsa OI. [Histaglobin treatment of allergic diseases in children]. Pediatr Akus Ginekol. 1977;(1):18–9.
65. Berardi G, Fornaci M, Rossi R. [Our experience in the treatment of asthmatic syndromes in children with intradermal histaglobin and gamma globulin]. Minerva Pediatr. 1970 Mar 24;22(12):556–9.
66. Morini V. [Preliminary note on the clinical trial of a combination of histamine, human gamma globulin and serotonin for the radical desensitizing therapy of allergic diseases, with special reference to bronchial asthma, headaches and allergic dermatoses. I]. Clin Ter. 1969 Sep 15;50(5):465–73.
67. Schrádi A, Bene J. [Results in the therapy of bronchial asthma using histaglobine]. Z Erkr Atmungsorgane Folia Bronchol. 1972;136(3):337–45.
68. Buczylko K, Latkowski B, Zalewski P. [Histaglobin in the treatment of recurrent inflammatory states of the respiratory tract in atopic children]. Rev Laryngol Otol Rhinol (Bord). 1988;109(2):191–4.
69. Latkowski B. [Histaglobin in the treatment of chronic otitis of allergic origin]. Rev Laryngol Otol Rhinol (Bord). 1980;101(5–6):235–40.
70. Matsui T, Sato F, Takenouchi S. [Clinical effects of histaglobin on allergic rhinitis]. Jibiinkoka. 1970 Nov;42(11):971–2.
71. Laurent J, Noirot C, Ansquer JC, Laurent G, Kestenbaum S, Lagrue G. [How to define the normal level of serum IgE in adults?]. Ann Med Interne (Paris). 1985;136(5):419–22.
72. Kim HS, Noh G. Effects of the immunoglobulin/histamine complex in chronic spontaneous urticaria focusing on remission induction. Allergy. 2022 Sep;77(9):2846–8.